Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has reached a significant point in its second human clinical study of 2021: HYPER-H21-2. The company announced that dosing has been completed in the study, which was comprised of 16 human volunteers who were pre- or mildly hypertensive; each participant received three separate doses of 150 mg each of DehydraTECH(TM) 2.0-enabled CBD versus a placebo. The study also included 24-hour continuous monitoring of blood pressure and heart rate, as well as evaluations of central arterial stiffness, physical activity and sleep quality. This key information will be assessed to evaluate the human response to DehydraTECH 2.0-enabled CBD. The company anticipates beginning a third human clinical study, HYPER-H21-3, following analysis of results from the first and second studies. In addition, Lexaria announced the expansion of its intellectual property portfolio with the allowance of its second patent in Japan. The patent is the 21st patent the company has been granted. Lexaria also noted that more than 7,000 stores across the country sell products that use its exclusive DehydraTECH technology. Some of those products include Cannadips, the original tobacco-free and nicotine-free CBD pouch; a growing number of New World CBD SKUs; and next-generation CHYLOSOMA(TM) formulations of CBD, CBG and CBN topical skin offerings. “Lexaria’s technology is enabling increased market share and sales growth for our continually growing list of corporate clients,” said Lexaria CEO Chris Bunka. “We are delighted to help these innovators of today and leaders of tomorrow offer their clients superior performance and experiences that competitors simply cannot match, and we are highly anticipatory of additional growth to come.”
About Lexaria Bioscience Corp.
Lexaria Bioscience’s proprietary drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company’s technology can be applied to many different ingestible product formats including foods, beverages, oral suspensions, tablets and capsules. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption of cannabinoids and nicotine by up to 5 to 10 times, reduce time of onset from one to two hours to minutes, and mask unwanted tastes; the technology is planned to be further evaluated for orally administered bioactive molecules including anti-viral drugs, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs) and more. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit http://www.LexariaBioScience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire is part of the InvestorBrandNetwork.